Still no light from TIGIT trials at ASCO23

While ASCO 2023 does not offer much in updates for the three current lead contenders for anti-TIGIT combinations in non-small cell lung cancer from Roche, Merck and Arcus pharmaceuticals, new data from AstraZeneca’s bi-specific PD1+TIGT offering in lung cancer were presented at ASCO, along with data from Roche’s tiragolumab in liver cancer, as well as with two further anti-TIGIT prospects from Chinese biotech (Zelgen and Shanghai Huaota). However, they all appear, so far, to follow a similar pattern to other TIGITs that have had detailed data presented such as that seen recently at the April AACR meeting.